Rani Therapeutics Holdings, Inc. (RANI) — Financial statements
Income statement, balance sheet, and cash flow for Rani Therapeutics Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↑58.9% | 1 | 0.00 | 0.00↓100.0% | 3 | |
| Cost of Revenue | 0.90 | 0.00↓100.0% | 0.82 | 0.00 | 0.00 | |
| Gross Profit | 0.73↓28.7% | 1↑225.1% | -0.82 | 0.00↓100.0% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 20↓24.3% | 27↓32.7% | 40↑8.2% | 37↑38.2% | 26 | |
| General & Administrative Expenses | 20↓17.6% | 24↓9.6% | 26↓1.4% | 27↓3.6% | 28 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↓17.6% | 24↓9.6% | 26↓1.4% | 27↓3.6% | 28 | |
| Other Expenses | -0.90↓124.2% | 4↑551.8% | -0.82 | 0.00 | 0.00 | |
| Operating Expenses | 39↓28.2% | 54↓16.8% | 65↑2.9% | 63↑16.8% | 54 | |
| Total Costs & Expenses | 40↓26.5% | 54↓17.8% | 66↑4.2% | 63↑16.8% | 54 | |
| Operating Results | ||||||
| Operating Income | -38↑28.1% | -53↑19.3% | -66↓4.2% | -63↓23.0% | -52 | |
| Depreciation & Amortization | 0.90↓12.5% | 1↑25.1% | 0.82↑50.0% | 0.55↑10.3% | 0.50 | |
| EBITDA | -37↑26.0% | -51↑22.6% | -65↓5.9% | -62↓18.4% | -52 | |
| EBIT | -38↑25.7% | -52↑22.0% | -66↓6.3% | -62↓18.3% | -53 | |
| Interest & Other Income | ||||||
| Net Interest Income | -2↑36.9% | -3↓83.3% | -2↓1107.9% | 0.18↑146.9% | -0.38 | |
| Interest Income | 0.83↓53.1% | 2↓46.6% | 3↑164.5% | 1↑1302.2% | 0.09 | |
| Interest Expense | 3↓42.6% | 5↓1.0% | 5↑374.8% | 1↑129.8% | 0.47 | |
| Non-Operating Income | 0.00↑100.0% | -2 | 0.00↑100.0% | -1↓227.1% | 0.98 | |
| Other Income / Expenses | -3↓111.3% | 23↑1405.8% | -2↓1107.9% | 0.18↑112.2% | -1 | |
| Income Before Tax | -41↓36.4% | -30↑55.8% | -68↓7.3% | -63↓19.3% | -53 | |
| Income Tax Expense | 0.00↓100.0% | 27 | 0.00↓100.0% | 0.07↑70.7% | 0.04 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -41↑27.6% | -57↑16.6% | -68↓7.2% | -63↓19.3% | -53 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -30↑1.1% | -30↑11.6% | -34↓11.1% | -31↓267.2% | -8 | |
| Bottom-Line Net Income | -30↑1.1% | -30↑11.6% | -34↓11.1% | -31↓267.2% | -8 | |
| EPS (Basic) | -0.45↑57.1% | -1.05↑21.1% | -1.33↓3.9% | -1.28↓204.8% | -0.42 | |
| EPS (Diluted) | -0.45↑57.1% | -1.05↑21.1% | -1.33↓3.9% | -1.28↓204.8% | -0.42 | |
| Weighted Average Shares | 66↑132.3% | 28↑11.6% | 26↑7.1% | 24↑21.9% | 20 | |
| Weighted Average Diluted Shares | 66↑132.3% | 28↑11.6% | 26↑7.1% | 24↑21.9% | 20 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.